Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tirbanibulin is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 33.00 |
Description | Tirbanibulin is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines). |
Targets&IC50 | Src HepG2:60 nM, Src PLC/PRF/5:13 nM, Src HuH7:(GI50)9 nM, Src Hep3B:26 nM |
In vitro | Tirbanibulin (KX2-391) is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 displays steep dose-response curves against Huh7 (GI50=9 nM), PLC/PRF/5 (GI50=13 nM), Hep3B (GI50=26 nM), and HepG2 (GI50=60 nM), four hepatic cell cancer (HCC) cell lines[1]. Tirbanibulin is evaluated in engineered Src driven cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI50 with 23 nM and 39 nM, respectively[2]. |
In vivo | In pre-clinical animal models of cancer, Tirbanibulin (p.o.) is shown to inhibit primary tumor growth and to suppress metastasis[2]. |
Synonyms | KX-01 (dihydrochloride), KX2-391 (dihydrochloride) |
Molecular Weight | 504.45 |
Formula | C26H31Cl2N3O3 |
CAS No. | 1038395-65-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33.33 mg/mL (66.07 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tirbanibulin dihydrochloride 1038395-65-1 Angiogenesis Tyrosine Kinase/Adaptors Src Tirbanibulin Tirbanibulin Dihydrochloride KX2-391 KX 01 KX-01 KX-01 (dihydrochloride) KX01 KX2-391 (dihydrochloride) inhibitor inhibit